Inventiva S.A.
OTC: IVEVF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Obenshain
- Employees
- 114
- Headquarters
- Daix, France
- IPO year
- 2019
- Market cap
- $499.2M
- Website
- https://www.inventivapharma.com
Loading IVEVF…
Loading profile data…Frequently asked questions about IVEVF
What does Inventiva S.A. (IVEVF) do?
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases. Its leading drug candidate, Lanifibranor, has successfully completed Phase IIb clinical trials for NASH treatment. T...
Where does IVEVF trade?
Inventiva S.A. (IVEVF) trades on the Other OTC.
What sector is IVEVF in?
Inventiva S.A. (IVEVF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inventiva S.A.?
Andrew Obenshain is the chief executive officer of Inventiva S.A. (IVEVF).
Where is Inventiva S.A. headquartered?
Inventiva S.A. is headquartered in France.
Does IVEVF pay a dividend?
Inventiva S.A. (IVEVF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IVEVF go public?
Inventiva S.A. (IVEVF) completed its initial public offering in 2019.